Serum levels of serum interleukin 2 receptor α or β-2-microglobulin from the large-tumor-burden therapeutic study
| . | Days after therapy . | ||||
|---|---|---|---|---|---|
| . | − 2 . | 14 . | 28 . | 42 . | |
| . | sIL-2Rα (× 103 pg/mL) . | β2M (μg/mL) . | β2M (μg/mL) . | β2M (μg/mL) . | β2M (μg/mL) . |
| Control | 37.39 ± 10.94 | 0.51 ± 0.26 | 7.17 ± 2.08 | NA | NA |
| HAT | 38.85 ± 14.12 | 0.74 ± 0.49 | 2.92 ± 1.433-151 | 7.86 ± 3.86 | 12.52 ± 8.52 |
| PRIT (nr) | 38.08 ± 12.20 | 0.59 ± 0.29 | 4.09 ± 1.963-150 | 11.20 ± 2.54 | NA |
| PRIT | 38.92 ± 13.26 | 0.78 ± 0.39 | 0.38 ± 0.423-151,3-152 | 1.62 ± 2.29 | 4.64 ± 3.86 |
| PRIT + HAT | 38.98 ± 13.65 | 0.98 ± 0.90 | 0.17 ± 0.183-151,3-152 | 0.04 ± 0.123-153 | 0.02 ± 0.083-155 |
| PRIT (ns) | 37.55 ± 11.21 | 0.67 ± 0.18 | 3.51 ± 0.923-151,3-154 | 14.25 ± 4.23 | NA |
| RIT | 36.81 ± 13.11 | 0.51 ± 0.28 | 4.06 ± 0.573-150,3-154 | 10.28 ± 3.53 | NA |
| . | Days after therapy . | ||||
|---|---|---|---|---|---|
| . | − 2 . | 14 . | 28 . | 42 . | |
| . | sIL-2Rα (× 103 pg/mL) . | β2M (μg/mL) . | β2M (μg/mL) . | β2M (μg/mL) . | β2M (μg/mL) . |
| Control | 37.39 ± 10.94 | 0.51 ± 0.26 | 7.17 ± 2.08 | NA | NA |
| HAT | 38.85 ± 14.12 | 0.74 ± 0.49 | 2.92 ± 1.433-151 | 7.86 ± 3.86 | 12.52 ± 8.52 |
| PRIT (nr) | 38.08 ± 12.20 | 0.59 ± 0.29 | 4.09 ± 1.963-150 | 11.20 ± 2.54 | NA |
| PRIT | 38.92 ± 13.26 | 0.78 ± 0.39 | 0.38 ± 0.423-151,3-152 | 1.62 ± 2.29 | 4.64 ± 3.86 |
| PRIT + HAT | 38.98 ± 13.65 | 0.98 ± 0.90 | 0.17 ± 0.183-151,3-152 | 0.04 ± 0.123-153 | 0.02 ± 0.083-155 |
| PRIT (ns) | 37.55 ± 11.21 | 0.67 ± 0.18 | 3.51 ± 0.923-151,3-154 | 14.25 ± 4.23 | NA |
| RIT | 36.81 ± 13.11 | 0.51 ± 0.28 | 4.06 ± 0.573-150,3-154 | 10.28 ± 3.53 | NA |
Control group did not receive any treatment. Humanized anti-Tac (HAT) group received HAT antibody 100 μg per week for 4 weeks. Pretargeting radioimmunotherapy (PRIT) and PRIT (no radionuclide, nr) groups received 400 μg HAT-SA pretargeting for 24 hours, 100 μg synthetic clearing agent (sCA) for 4 hours, and 1 μg DOTA-biotin labeled with 250 and 0 μCi (9.25 and 0 MBq) bismuth 213 (213Bi). PRIT + HAT group is the combination of PRIT and HAT.
PRIT (nonspecific, ns) group received 400 μg nonspecific antibody-streptavidin conjugate (B3-SA) pretargeting for 24 hours, 100 μg sCA for 4 hours, and 1 μg DOTA-biotin labeled with 250 μCi (9.25 MBq) 213Bi. Radioimmunotherapy (RIT) group received 50 μCi (1.85 MBq) 213Bi labeled HAT. NA, not available (no mice surviving).
P < .005 compared with control group.
P < .0001 compared with control group.
P < .0001 compared with HAT group.
P < .05 compared with PRIT group.
P < .005 compared with PRIT group.
P < .0001 compared with PRIT group.